Ronald Levy | |
|---|---|
| Alma mater | |
| Known for | Rituxan |
| Children | 3 |
| Awards | 2016 AACR-CRI Lloyd J. Old Award in Cancer Immunology |
| Scientific career | |
| Fields | Oncology |
| Institutions | |
Ronald Levy is an American physician and scientist at Stanford University. He specializes in lymphoma, including non-Hodgkin lymphoma, Burkitt's lymphoma and Hodgkin's disease.[1] His research investigates how the immune system can be harnessed to fight lymphoma. His work has led to the concept that antibodies can be used as personalized anticancer drugs and to the development of an antibody-based drug, Rituxan, that is widely used to treat lymphoma.[2]